Fig. 2. SNAKA51 promotes ligand-binding to ₅ß₁ integrin, and SNAKA51 binding to ₅ß₁ integrin is increased in the presence of ligand. Using a solid-phase ligand-binding assay, the binding of biotinylated FnIII (6-10) (0.1 µg/ml) to ₅ß₁ integrin was measured. (a) Binding of FnIII (6-10) to directly coated placental ₅ß₁ integrin and to anti-Fc, captured recombinant integrin in the presence and absence of SNAKA51, 12G10, or K20. Statistical analysis was performed using a 2-tailed t-test in comparison to the control without antibody. ^* P<0.005, ^**P<0.0005. (b) Dose-dependent binding of biotinylated SNAKA51 to K20 tethered placental ₅ß₁ integrin in the presence or absence of FnIII (6-10) (20 µg/ml).